Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-010
2022-501417-31-01Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab, vibostolimab + pembrolizumab and vibostolimab in melanoma (2 arms), sponsored by Merck & Co. Primary endpoint: Recurrence-Free Survival. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-501417-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501417-31-01.